Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
Objective: To better understand exenatide's role in the treatment of type 2 diabetes, this analysis assessed its cost-effectiveness in comparison to an intermediate (NPH) and long-acting insulin (glargine). Exenatide is a recently approved medication for the treatment of type 2 diabetes for use...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Centro de Investigaciones y Publicaciones Farmaceuticas,
2006-09-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Primjerak 1 | Dostupno |